These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33259782)

  • 1. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
    Nelson AL; Kaunitz AM; Kroll R; Simon JA; Poindexter AN; Castaño PM; Ackerman RT; Flood L; Chiodo JA; Garner EI;
    Contraception; 2021 Mar; 103(3):137-143. PubMed ID: 33259782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    Kaunitz AM; Archer DF; Mishell DR; Foegh M
    Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new low-dose transdermal contraceptive system (Twirla
    Nelson AL
    Ther Deliv; 2021 Jul; 12(7):501-514. PubMed ID: 34098739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
    Bannemerschult R; Hanker JP; Wünsch C; Fox P; Albring M; Brill K
    Contraception; 1997 Nov; 56(5):285-90. PubMed ID: 9437556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
    Kaunitz AM; Portman D; Westhoff CL; Archer DF; Mishell DR; Rubin A; Foegh M
    Obstet Gynecol; 2014 Feb; 123(2 Pt 1):295-303. PubMed ID: 24402597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model.
    Stanczyk FZ; Archer DF; Lohmer LRL; Pirone J; Previtera M; Korner P
    PLoS One; 2022; 17(12):e0279640. PubMed ID: 36574387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
    Kaunitz AM; Portman D; Westhoff CL; Archer DF; Mishell DR; Foegh M
    Contraception; 2015 Mar; 91(3):204-10. PubMed ID: 25582984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
    Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
    Ankrom W; Jackson Rudd D; Zhang S; Fillgrove KL; Gravesande KN; Matthews RP; Brimhall D; Stoch SA; Iwamoto MN
    J Int AIDS Soc; 2021 Dec; 24(12):e25858. PubMed ID: 34935295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL; Reinecke I; Bangerter K; Merz M
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).
    Archer DF; Maheux R; DelConte A; O'Brien FB
    Contraception; 1997 Mar; 55(3):139-44. PubMed ID: 9115001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).
    Archer DF; Maheux R; DelConte A; O'Brien FB
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):39-44. PubMed ID: 10561674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
    Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
    Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
    Kroll R; Reape KZ; Margolis M
    Contraception; 2010 Jan; 81(1):41-8. PubMed ID: 20004272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis Approach.
    Lingineni K; Chaturvedula A; Cicali B; Cristofoletti R; Wendl T; Hoechel J; Brown JD; Vozmediano V; Schmidt S
    Clin Pharmacol Ther; 2022 Feb; 111(2):509-518. PubMed ID: 34674227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.